sur Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences AG Reports Success in Liver Diagnostics
Xlife Sciences AG has announced significant advancements in diagnostic solutions through its subsidiary, x-nuclear diagnostics GmbH. The company has successfully developed the PET tracer DAZAmed, specifically designed for visualizing liver function.
DAZAmed has shown high efficacy in initial applications, successfully diagnosing patients. Safety, tolerability, and efficacy have been confirmed through toxicity studies in animals and trials in humans.
The production of DAZAmed precursors, compliant with GMP standards, is managed by inflamed pharma GmbH, another subsidiary of Xlife Sciences AG. This step is crucial for the clinical commercialization expected in the third quarter of 2024.
Oliver R. Baumann, CEO of Xlife Sciences AG, commented on the milestone, emphasizing the innovation and commitment of their team.
These advancements underline Xlife Sciences AG's mission to enhance healthcare technologies and improve diagnostic access.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xlife Sciences AG